Skip to main content

Advertisement

SpringerLink
Log in

Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purposes

Trastuzumab is known to be effective for early and advanced stages of breast cancer but optimal duration for early-stage breast cancer (EBC) is not well known. We evaluated the efficacy and toxicity of 9- and 52-week trastuzumab therapy for EBC retrospectively.

Methods

In this multicenter study, the medical records of all patients with EBC were analyzed in 8 centers retrospectively. Totally consecutive, 479 female patients who received trastuzumab in the adjuvant treatment were evaluated for disease-free survival (DFS), overall survival (OS), efficacy, and toxicity.

Results

There were 181 (37.8 %) and 298 (62.2 %) patients in the 9- and 52-week trastuzumab groups, respectively. Median follow-up was 30.6 months (5.7–68.9) in the 9-week trastuzumab group and 29.3 months (5.9–59.6) in the 52-week trastuzumab group. Thirty-six month DFS was 90 and 85 % (P = 0.132) in the 9- and 52-week trastuzumab treatment groups, respectively, and 36-month OS was 96 and 97 % in the 9- and 52-week trastuzumab groups, respectively (P = 0.779). Symptomatic cardiotoxicity was observed in 1 (0.6 %) patient in the 9-week trastuzumab group and in 4 (1.3 %) patients in the 52-week trastuzumab group.

Conclusions

In this study, similar outcomes were found in the 9- and 52-week trastuzumab treatment groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Boekhout AH, Beijnen JH, Schellens JH (2011) Trastuzumab. Oncologist 16:800–810

    Article  PubMed  CAS  Google Scholar 

  • Chen T, Xu T, Li Y, Liang C, Chen J, Lu Y, Wu Z, Wu S (2006) Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev 37:312–320

    Article  Google Scholar 

  • Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2006) Publish Date: August 9, 2006. www.eortc.be/services/doc/ctc/ctcaev3.pdf. Accessed 2011 July 29

  • Costa RB, Kurra G, Greenberg L, Geyer CE (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 21:2153–2160

    Article  PubMed  CAS  Google Scholar 

  • Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900–2902

    Article  PubMed  CAS  Google Scholar 

  • Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R (2011) Herceptin Adjuvant (HERA) Trial Study Team Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236–244

    Article  PubMed  CAS  Google Scholar 

  • Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700–5706

    Article  PubMed  Google Scholar 

  • Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J, FinHer Study Investigators (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820

    Article  PubMed  CAS  Google Scholar 

  • Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27:5685–5692

    Article  PubMed  CAS  Google Scholar 

  • McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA (2011) Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 117:5461–5468

    Article  PubMed  CAS  Google Scholar 

  • Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103–112

    PubMed  CAS  Google Scholar 

  • Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011a) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366–3373

    Article  PubMed  CAS  Google Scholar 

  • Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB (2011b) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29:4491–4497

    Article  PubMed  CAS  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  PubMed  CAS  Google Scholar 

  • Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684

    Article  PubMed  CAS  Google Scholar 

  • Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, Murakami S, Yamamoto Y, Kashiwaba M, Iwata H, Uemura Y, Ohashi Y (2011) Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol 41:709–712

    Article  PubMed  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712

    Article  PubMed  CAS  Google Scholar 

  • Slamon D, Eiermann W, Robert N (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94(Suppl 1):S5a

    Google Scholar 

  • Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283

    Article  PubMed  CAS  Google Scholar 

  • Spielmann M, Roché H, Delozier T, Canon JL, Romieu G, Bourgeois H, Extra JM, Serin D, Kerbrat P, Machiels JP, Lortholary A, Orfeuvre H, Campone M, Hardy-Bessard AC, Coudert B, Maerevoet M, Piot G, Kramar A, Martin AL, Penault-Llorca F (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129–6134

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Gazi University, 06500, Besevler, Cankaya, Ankara, Turkey

    Onder Tonyali, Ugur Coskun, Mustafa Benekli, Aytug Uner, Deniz Yamac & Suleyman Buyukberber

  2. Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey

    Nur Sener, Ramazan Yildiz & Mahmut Gumus

  3. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkey

    Mevlude Inanc & Halit Karaca

  4. Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey

    Tulay Akman & Olcun Umit Unal

  5. Department of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey

    Berna Oksuzoglu & Oznur Bal

  6. Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey

    Nuriye Yildirim Ozdemir

  7. Department of Medical Oncology, Konya Numune Education and Reseach Hospital, Konya, Turkey

    Dogan Yazilitas

  8. Department of Medical Oncology, Ankara Ataturk Education and Research Hospital, Ankara, Turkey

    Umut Demirci

Authors
  1. Onder Tonyali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ugur Coskun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nur Sener
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mevlude Inanc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tulay Akman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Berna Oksuzoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nuriye Yildirim Ozdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dogan Yazilitas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mustafa Benekli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Aytug Uner
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Deniz Yamac
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Umut Demirci
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ramazan Yildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Halit Karaca
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Olcun Umit Unal
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Oznur Bal
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Mahmut Gumus
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Suleyman Buyukberber
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Anatolian Society of Medical Oncology (ASMO)

Corresponding author

Correspondence to Onder Tonyali.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tonyali, O., Coskun, U., Sener, N. et al. Nine-week trastuzumab treatment versus 52-week trastuzumab treatment for HER2-positive early-stage breast cancer. J Cancer Res Clin Oncol 138, 2145–2151 (2012). https://doi.org/10.1007/s00432-012-1296-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-012-1296-x

Keywords

Search

Navigation